Literature DB >> 17392553

High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes.

Raffaella Buzzetti1, Sergio Di Pietro, Andrea Giaccari, Antonio Petrone, Mattia Locatelli, Concetta Suraci, Marco Capizzi, Maria Luisa Arpi, Elena Bazzigaluppi, Francesco Dotta, Emanuele Bosi.   

Abstract

OBJECTIVE: The aim of the present study was to define heterogeneity of adult-onset autoimmune diabetes based on characterization of GAD antibodies (GADAs). RESEARCH DESIGN AND METHODS: Patients enrolled in a nationwide survey, the Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study, have been screened for GADAs and IA-2 antibodies (IA-2As) and further characterized for GADA titer, antibodies to thyroid peroxidase (TPO), and HLA DRB1-DQB1 polymorphisms.
RESULTS: Of 4,250 consecutive type 2 diabetic patients, 4.5% had either GADAs and/or IA-2As. Patients with autoimmune diabetes showed a clinical phenotype significantly different from that of type 2 diabetes, including higher fasting glucose and A1C, lower BMI and uric acid, lower prevalence of metabolic syndrome and its components, and higher frequency of TPO antibodies. More interestingly, analysis of GADA titers showed a bimodal distribution that identified two subgroups of patients with high (>32 GADA arbitrary units) and low (< or =32 GADA arbitrary units) GADA titers. Compared with those with low GADA titers, patients with high GADA titers had more prominent traits of insulin deficiency and a profile of more severe autoimmunity resulting in higher A1C, lower BMI, a lower prevalence of metabolic syndrome and its components (P < 0.02 for all), a higher prevalence of IA-2As, TPO antibodies (P < 0.003 for both), and DRB1*03-DQB1*0201 (50 vs. 26.8%, P = 0.001), and a decreasing frequency of DQB1*0602 and DRB1*0403 (from type 2 to low and to high GADA titer autoimmune diabetes; P < 0.001 for trend for both comparisons).
CONCLUSIONS: GADA titers identify two subgroups of patients with adult-onset autoimmune diabetes having distinct clinical, autoimmune, and genetic features.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17392553     DOI: 10.2337/dc06-1696

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  69 in total

1.  Latent autoimmune diabetes in adults (LADA) is dead: long live autoimmune diabetes!

Authors:  O Rolandsson; J P Palmer
Journal:  Diabetologia       Date:  2010-03-25       Impact factor: 10.122

2.  Results of the First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults further highlight the need for a novel diabetes classification system.

Authors:  Theocharis Koufakis; Spyridon N Karras; Pantelis Zebekakis; Kalliopi Kotsa
Journal:  Ann Transl Med       Date:  2018-12

Review 3.  Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus.

Authors:  Elena Pipi; Marietta Marketou; Alexandra Tsirogianni
Journal:  World J Diabetes       Date:  2014-08-15

4.  Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy.

Authors:  C D Andersen; L Bennet; L Nyström; U Lindblad; E Lindholm; L Groop; O Rolandsson
Journal:  Diabetologia       Date:  2012-10-25       Impact factor: 10.122

5.  Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years.

Authors:  Mette K Andersen; Virve Lundgren; Joni A Turunen; Carol Forsblom; Bo Isomaa; Per-Henrik Groop; Leif Groop; Tiinamaija Tuomi
Journal:  Diabetes Care       Date:  2010-09       Impact factor: 19.112

Review 6.  Should There be Concern About Autoimmune Diabetes in Adults? Current Evidence and Controversies.

Authors:  Jakob Appel Østergaard; Esben Laugesen; R David Leslie
Journal:  Curr Diab Rep       Date:  2016-09       Impact factor: 4.810

7.  Heterogeneity of patients with latent autoimmune diabetes in adults: linkage to autoimmunity is apparent only in those with perceived need for insulin treatment: results from the Nord-Trøndelag Health (HUNT) study.

Authors:  Maria A Radtke; Kristian Midthjell; Tom I Lund Nilsen; Valdemar Grill
Journal:  Diabetes Care       Date:  2008-11-10       Impact factor: 17.152

8.  GAD antibody positivity predicts type 2 diabetes in an adult population.

Authors:  Virve M Lundgren; Bo Isomaa; Valeriya Lyssenko; Esa Laurila; Pasi Korhonen; Leif C Groop; Tiinamaija Tuomi
Journal:  Diabetes       Date:  2009-10-28       Impact factor: 9.461

9.  Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4.

Authors:  Vito Lampasona; Antonio Petrone; Claudio Tiberti; Marco Capizzi; Marialuisa Spoletini; Sergio di Pietro; Marco Songini; Sara Bonicchio; Francesco Giorgino; Ezio Bonifacio; Emanuele Bosi; Raffaella Buzzetti
Journal:  Diabetes Care       Date:  2009-10-06       Impact factor: 19.112

Review 10.  Beta-cell protection and therapy for latent autoimmune diabetes in adults.

Authors:  Simona Cernea; Raffaella Buzzetti; Paolo Pozzilli
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.